Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application: [review]
Int. braz. j. urol
;
36(3): 273-282, May-June 2010.
Article
in English
| LILACS
| ID: lil-555186
ABSTRACT
Bladder cancer is a common and frequently lethal cancer. Natural history studies indicate two distinct clinical and molecular entities corresponding to invasive and non-muscle invasive disease. The high frequency of recurrence of noninvasive bladder cancer and poor survival rate of invasive bladder cancer emphasizes the need for novel therapeutic approaches. These mechanisms of tumor development and promotion in bladder cancer are strongly associated with several growth factor pathways including the fibroblast, epidermal, and the vascular endothelial growth factor pathways. In this review, efforts to translate the growing body of basic science research of novel treatments into clinical applications will be explored.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Urinary Bladder Neoplasms
/
Receptors, Fibroblast Growth Factor
/
Vascular Endothelial Growth Factor A
/
ErbB Receptors
Limits:
Humans
Language:
English
Journal:
Int. braz. j. urol
Journal subject:
Urology
Year:
2010
Type:
Article
Affiliation country:
United States
Institution/Affiliation country:
University of Colorado Denver/US
Similar
MEDLINE
...
LILACS
LIS